Beijing Hotgen Biotech Co., Ltd.

Equities

688068

CNE100003P82

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 03:30:00 15/05/2024 am IST 5-day change 1st Jan Change
29.55 CNY -1.50% Intraday chart for Beijing Hotgen Biotech Co., Ltd. -8.66% -28.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Beijing Hotgen Biotech to Buy Kaijing Gene Technology for 11 Million Yuan MT
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on February 8, 2024. CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares. CI
Beijing Hotgen Biotech Co., Ltd. authorizes a Buyback Plan. CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) dropped from S&P Global BMI Index CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) added to S&P Global BMI Index CI
Hangzhou Oriomics Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Shenzhen Dachen Caizhi Venture Capital Management Co., Ltd., Tao Capital, Beijing Hotgen Biotech Co., Ltd. and other investors CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022. CI
Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback announced on September 6, 2022 has closed with 2,861,477 shares, representing 3.12% for CNY 166.45 million. CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022. CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022. CI
Beijing Hotgen Biotech Unit Secures Registration Certificate For Two Devices MT
Beijing Hotgen Biotech Gets Registration Certificate for Hepatitis B Assay Kit; Shares Fall 4% MT
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022. CI
Beijing Hotgen Biotech’s Board Approves Up to $43 Million Share Buyback MT
Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares. CI
Beijing Hotgen Biotech Co., Ltd. authorizes a Buyback Plan. CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chart Beijing Hotgen Biotech Co., Ltd.
More charts
Beijing Hotgen Biotech Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. The Company's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The Company primarily conducts its businesses in domestic and overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. 688068 Stock
  4. News Beijing Hotgen Biotech Co., Ltd.
  5. Beijing Hotgen Biotech to Buy Kaijing Gene Technology for 11 Million Yuan
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW